BNP Paribas Financial Markets Boosts Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)

BNP Paribas Financial Markets increased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 110.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 72,963 shares of the medical research company's stock after buying an additional 38,238 shares during the period. BNP Paribas Financial Markets owned 0.06% of NeoGenomics worth $1,076,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Blue Trust Inc. raised its stake in shares of NeoGenomics by 107.2% during the second quarter. Blue Trust Inc. now owns 2,331 shares of the medical research company's stock worth $32,000 after buying an additional 1,206 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in NeoGenomics during the 2nd quarter worth $57,000. KBC Group NV grew its holdings in NeoGenomics by 33.1% during the 3rd quarter. KBC Group NV now owns 4,530 shares of the medical research company's stock worth $67,000 after acquiring an additional 1,127 shares during the period. FMR LLC grew its holdings in NeoGenomics by 7.6% during the 3rd quarter. FMR LLC now owns 13,255 shares of the medical research company's stock worth $196,000 after acquiring an additional 931 shares during the period. Finally, Banque Cantonale Vaudoise grew its holdings in NeoGenomics by 10.2% during the 2nd quarter. Banque Cantonale Vaudoise now owns 17,575 shares of the medical research company's stock worth $244,000 after acquiring an additional 1,633 shares during the period. Institutional investors own 98.50% of the company's stock.

NeoGenomics Price Performance

NASDAQ:NEO traded down $0.26 on Wednesday, hitting $18.17. The company had a trading volume of 537,888 shares, compared to its average volume of 799,778. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of -29.79 and a beta of 1.24. The company has a current ratio of 1.99, a quick ratio of 1.91 and a debt-to-equity ratio of 0.37. The firm has a 50 day moving average of $15.24 and a two-hundred day moving average of $15.09. NeoGenomics, Inc. has a 52 week low of $12.77 and a 52 week high of $21.22.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.04. The firm had revenue of $167.80 million during the quarter, compared to the consensus estimate of $167.00 million. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The company's revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.06) earnings per share. On average, research analysts anticipate that NeoGenomics, Inc. will post -0.17 earnings per share for the current year.

Insider Buying and Selling at NeoGenomics

In related news, General Counsel Alicia C. Olivo sold 5,175 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $15.36, for a total transaction of $79,488.00. Following the transaction, the general counsel now directly owns 37,129 shares of the company's stock, valued at $570,301.44. This represents a 12.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.30% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on NEO. Jefferies Financial Group began coverage on shares of NeoGenomics in a report on Tuesday. They issued a "buy" rating and a $22.00 price target for the company. Benchmark reaffirmed a "buy" rating and issued a $18.00 price objective on shares of NeoGenomics in a research report on Tuesday, September 24th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $19.00 price objective on shares of NeoGenomics in a research report on Wednesday, November 6th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $20.44.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.